EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

The Efficacy and Safety of Inhaled Antibiotics for the Treatment of Bronchiectasis in Adults

Ricardo Cordeiro, Hayoung Choi, Charles S Haworth, James D Chalmers

CHEST · 2024-07 · 166 (1) · 61-80

DOI: 10.1016/j.chest.2024.01.045 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift CHEST, 2024-07. Verfasst von Ricardo Cordeiro und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, Centro Hospitalar do Oeste, Torres Vedras, Portugal. Hauptthemen laut MEDLINE: Bronchiectasis, Anti-Bacterial Agents. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Respiratory Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Inhaled antibiotics are recommended conditionally by international bronchiectasis guidelines for the treatment of patients with bronchiectasis, but results of individual studies are inconsistent. A previous meta-analysis demonstrated promising results regarding the efficacy and safety of inhaled antibiotics in bronchiectasis. Subsequent publications have supplemented the existing body of evidence further in this area. RESEARCH QUESTION: To what extent do inhaled antibiotics demonstrate both efficacy and safety as a treatment option for adults with bronchiectasis? STUDY DESIGN AND METHODS: Systematic review and meta-analysis of randomized controlled trials of inhaled antibiotics in adult patients with bronchiectasis. We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials.gov for eligible studies. Studies were included if they enrolled adults with bronchiectasis diagnosed by CT imaging and had a treatment duration of at least 4 weeks. The primary end point was exacerbation frequency, with additional key efficacy end points including severe exacerbations, bacterial load, symptoms, quality of life, and FEV1. Data were pooled through random-effects meta-analysis. RESULTS: Twenty studies involving 3,468 patients were included. Inhaled antibiotics were associated with reduced number of patients with exacerbations (risk ratio, 0.85; 95% CI, 0.75-0.96), a slight reduction in exacerbation frequency (rate ratio [RR], 0.78; 95% CI, 0.68-0.91), a probable reduction in the frequency of severe exacerbations (RR, 0.48; 95% CI, 0.31-0.74), and a likely slight increase in time to first exacerbation (hazard ratio, 0.80; 95% CI, 0.68-0.94). Inhaled antibiotics likely lead to a slight increase in the Quality of Life Questionnaire-Bronchiectasis respiratory symptom score (mean difference, 2.51; 95% CI, 0.44-4.31) and may reduce scores on the St. George Respiratory Questionnaire (mean difference, -3.13; 95% CI, -5.93 to -0.32). Bacterial load consistently was reduced, but FEV1 was not changed with treatment. Evidence suggests little to no difference in adverse effects between groups (OR, 0.99; 95% CI, 0.75-1.30). Antibiotic-resistant organisms likely were increased by treatment. INTERPRETATION: In this systematic review and meta-analysis, inhaled antibiotics resulted in a slight reduction in exacerbations, a probable reduction in severe exacerbations, and a likely slight improvement in symptoms and quality of life in adults with bronchiectasis. TRIAL REGISTRY: International Prospective Register of Systematic Reviews; No.: CRD42023384694; URL: https://www.crd.york.ac.uk/prospero/.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BronchiectasisAnti-Bacterial AgentsHumansAdministration, InhalationAdultQuality of LifeTreatment Outcome

Stichwörter der Autor:innen

antibioticsbronchiectasisinhalationmeta-analysistherapeutics

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pulmonology, Centro Hospitalar do Oeste, Torres Vedras, Portugal.
  • Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea.
  • Cambridge Centre for Lung Infection, Royal Papworth Hospital NHS Foundation Trust, University of Cambridge, Cambridge, England; Department of Medicine, University of Cambridge, Cambridge, England.
  • Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland. Electronic address: jchalmers@dundee.ac.uk.

Förderung

  • European Respiratory Society

Zitieren

APA

Cordeiro, R., Choi, H., Haworth, C. S., & Chalmers, J. D. (2024). The Efficacy and Safety of Inhaled Antibiotics for the Treatment of Bronchiectasis in Adults. CHEST, 166(1), 61-80. https://doi.org/10.1016/j.chest.2024.01.045

Vancouver

Cordeiro R, Choi H, Haworth CS, Chalmers JD. The Efficacy and Safety of Inhaled Antibiotics for the Treatment of Bronchiectasis in Adults. CHEST. 2024;166(1):61-80. doi:10.1016/j.chest.2024.01.045

BibTeX
@article{Cordeiro2024,
  author = {Cordeiro, Ricardo and Choi, Hayoung and Haworth, Charles S and Chalmers, James D},
  title = {The Efficacy and Safety of Inhaled Antibiotics for the Treatment of Bronchiectasis in Adults},
  journal = {CHEST},
  year = {2024},
  volume = {166},
  number = {1},
  pages = {61--80},
  doi = {10.1016/j.chest.2024.01.045}
}
Kostenlos starten →